Thursday, June 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 66 of 1,261

  1. WO 2025023851

    ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE

    BIAL PORTELA & CA SA [PT] · Granted Jan 30, 2025 · Expires Jan 25, 2045

    granted

  2. US 12209140

    Therapeutics for the treatment of glaucoma

    Regents of the University of Minnesota · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  3. US 12209120

    Activatable anti-VEGF scFv

    The Regents of the University of California · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  4. US 12209135

    Anti-CD45 antibodies and conjugates thereof

    Vor Biopharma Inc. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  5. US 12208123

    Compositions and methods for the treatment of skin conditions

    DERMATA THERAPEUTICS, INC. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  6. US 12208071

    Glucagon receptor antagonists

    Ligand Pharmaceuticals Incorporated · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  7. US 12209119

    Method of treating rheumatoid arthritis using antibodies to oxidized phospholipids

    The Regents of the University of California · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  8. US 12208069

    Antibiofilm formulations

    Arizona Board of Regents on Behalf of Northern Arizona University · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  9. US 12208099

    Combination therapies

    Mirati Therapeutics, Inc. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  10. US 12209116

    Recombinant human C1 esterase inhibitor and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  11. US 12210017

    Peptides representing epitopes from filoviruses

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  12. US 12208167

    Coated tablets for pH-dependent release of benzgalantamine

    ALPHA COGNITION INC. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  13. US 12208092

    Compositions and methods for administering paltusotine to patients with hepatic impairment

    CRINETICS PHARMACEUTICALS, INC. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  14. US 12208093

    Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)

    THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  15. US 12208227

    Precision bio-chemotronic system

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  16. US 12209085

    RET inhibitors, pharmaceutical compositions and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  17. US 12209142

    SARS-CoV-2 epitope-targeted peptide immunostimulants

    The United States of America as represented by the Secretary of the Army · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  18. US 12209238

    CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  19. US 12209180

    Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  20. US 12209255

    Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof

    Astellas Institute for Regenerative Medicine · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  21. US 12209073

    Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor

    KIORA PHARMACEUTICALS GmbH · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  22. US 12209256

    System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  23. US 12208148

    Dental restorative curable composition

    KURARAY NORITAKE DENTAL INC. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  24. US 12209240

    Antisense antibacterial compounds and methods

    The Board of Regents of the University of Texas System · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.